Navigation Links
Timm Medical Technologies and Ferring Pharmaceuticals Enter Exclusive Co-Promotion Agreement for Prosed(R) DS

MINNEAPOLIS, Oct. 14 /PRNewswire/ -- Timm Medical Technologies, Inc., a specialist Urology company, announced today its exclusive co-promotion agreement with Ferring Pharmaceuticals Inc., a Swiss-based biopharmaceutical company, for Prosed® DS (methenamine, phenyl salicylate, methylene blue, benzoic acid, hyoscyamine sulfate) in the United States.

Under the agreement, Timm Medical will be responsible for promoting Prosed® DS to urologists and retail pharmacists in the United States. Ferring will continue to promote Prosed® DS to physicians in the United States and will retain responsibility for manufacturing, supply and regulatory affairs. Financial terms of the agreement were not disclosed.

Prosed® DS is a urinary analgesic, antiseptic and antispasmodic combination. Prosed® DS has a long history of use for the treatment of pain and discomfort of the lower urinary tract.

"We are excited to partner with Ferring Pharmaceuticals to promote this well-established treatment for urinary discomfort," commented David Talen, President of Timm Medical. "Timm Medical and Ferring Pharmaceuticals share a commitment to urologists and the care of their patients. Timm Medical's flagship product, the Osbon ErecAid, has a 30-year history of providing safe, effective and reliable treatment for men suffering from erectile dysfunction. Prosed® DS has the same outstanding reputation as an effective treatment for the pain associated with urological procedures, inflammatory diseases and infections, and represents a natural complement to our product portfolio."

About Timm Medical

Timm Medical is a specialist urology company owned by affiliates of Paul Capital Healthcare. Timm Medical offers products in the areas of erectile function and incontinence. Through its sales force in the United States, Timm calls on over 3,000 urology practices. In addition, Timm distributes products via a 60+ international distributor network. For more information, contact David Talen, President or visit

About Ferring Pharmaceuticals Inc.

Ferring Pharmaceuticals Inc. is a subsidiary of Ferring Pharmaceuticals, a privately owned, international pharmaceutical company. Ferring Pharmaceuticals offers a line of infertility, urology, and orthopaedic products in the U.S. market. They include: BRAVELLE® (urofollitropin for injection, purified), MENOPUR® and REPRONEX® (menotropins for injection, USP), NOVAREL® (chorionic gonadotropin for injection, USP), ENDOMETRIN® (progesterone) Vaginal Insert, 100 mg, FIRMAGON® (degarelix for injection), PROSED® DS (methenamine, phenyl salicylate, methylene blue, benzoic acid, hyoscyamine sulfate), DESMOPRESSIN, and EUFLEXXA® (1% sodium hyaluronate).

Ferring Pharmaceuticals specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, orthopaedics, gastroenterology, obstetrics/gynecology, and infertility. For more information, call 1-888-FERRING (1-888-337-7464) or visit

SOURCE Timm Medical Technologies, Inc.

SOURCE Timm Medical Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardiva Medical, Inc. Announces the Departure of its President and his Appointment as CEO of Innovative Energy, Inc.
2. Vibrant Exhibit Hall Features Innovative Medical Technology at AdvaMed 2009
3. Luminous Medical, Inc. Secures Exclusive Rights to Glucose Sensor for Its Automated Glucose Monitor
4. Growing Supply Chain Complexity Increasing Impact on Medical Device Company Operations
5. Award-Winning Medical Technology From Germany
6. Cantel Medicals Crosstex Subsidiary Launches New Specially Treated Face Mask Effective Against H1N1 Influenza
7. ATS Medical Announces Receipt of CE Mark for the New ATS CryoMaze 10-S Probe
8. Sonitus Medical Technology Ranks #1 on Cleveland Clinics Top 10 Medical Innovations for 2010
9. Medical Technology Executives Descend on D.C. as AdvaMed 2009: The MedTech Conference Kicks Off and Health Care Debate Continues
10. MDMA Board Unanimously Opposes Medical Device Tax
11. Fresenius Medical Care, N.A. Has Selected VitalRemedyMDs VitalProteinRx(TM) As Its Bar of Choice for Protein Replacement in Dialysis Patients
Post Your Comments:
(Date:12/1/2015)... 2015   MabVax Therapeutics Holdings, Inc . (OTCQB: ... has filed an Investigational New Drug Application (IND) with ... Company,s lead fully human antibody product HuMab 5B1 as ... to initiate the Phase I clinical trial early in ... The planned Phase I trial will evaluate the ...
(Date:12/1/2015)... FRANCISCO , Dec. 1, 2015  InCarda Therapeutics, ... development and commercialization of therapies for cardiovascular conditions via ... a subsidiary business in Australia . ... trial in Australia in the ... leading investigators and medical centers in Adelaide ...
(Date:12/1/2015)... , Dec. 1, 2015  The migration ... to develop shared care plans that help patients ... care plans will be digitally enabled, incorporate care ... needs and desires. They will also allow all ... patient,s health journey is optimal. That is the ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... The Multiple System Atrophy Coalition has announced ... Multiple System Atrophy (MSA) research, timed today to coincide with Giving Tuesday 2015, a ... including their ability to work and be productive, to do simple daily activities like ...
(Date:12/1/2015)... ... December 02, 2015 , ... ClinicoEconomics and Outcomes Research ... of treatment for osteoporosis ”. , As corresponding author Dr Ankita Modi says ... with osteoporosis. Based on a large US managed care database, women aged 55 ...
(Date:12/1/2015)... ... December 01, 2015 , ... According to an ... has filed a discrimination claim against the U.S. Department of Health and Human Services, ... Care Act (ACA) plans are breaking the clause in the law prohibiting the denial ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Paul Vitenas, one of the ... named by MedEsthetics magazine as the Best Single Physician Practice in the nation. Dr. ... elite aesthetic physicians honored by the industry publication. , Dr. Vitenas said he ...
(Date:12/1/2015)... York, NY (PRWEB) , ... December 01, 2015 ... ... epidemic in the 1980s we have seen vast improvements in scientific research and ... made significant strides, providing increased hope and relief to those affected by HIV/AIDS. ...
Breaking Medicine News(10 mins):